<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 5.0.1.2 [08/21/2012 06:02:49 PM] by DataTracks -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.5.8 on Monday, September 10, 2012 07:55:13 PM -->
<xbrli:xbrl xmlns:mgt="http://mgt.com/20120630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="mgt-20120630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_FYE_31-Dec-2006">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2006-01-01
</xbrli:startDate>
<xbrli:endDate>
2006-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:MoneygateGroupMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:MoneygateGroupMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_31-Mar-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:DunamisCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_31-Mar-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:MoneygateGroupMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:DunamisCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_6ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:LaddcapValuePartnersIiiLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_3ME_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:LaddcapValuePartnersIiiLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:DunamisCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25-Jun-2012_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25-Jun-2012_AwardTypeAxis_FarmerDirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgt:FormerDirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_3ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:AllOptionPlansMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:MedicsightPlanJMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_OfficersAndCertainEmployeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">mgt:OfficersAndCertainEmployeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_EachCurrentIndependentDirectorOfBoardMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">mgt:EachCurrentIndependentDirectorOfBoardMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_PlanNameAxis_StockOptionPlanJMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:StockOptionPlanJMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2012_IssuanceOfWarrantsAxis_BlackScholesPricingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="mgt:IssuanceOfWarrantsAxis">mgt:BlackScholesPricingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:MedicsightPlanJMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_AwardTypeAxis_FarmerDirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgt:FormerDirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtGamingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:UnallocatedCorporateOtherMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:SoftwareAndDevicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgt:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14-Aug-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_ParentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_ParentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:AllOptionPlansMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgt:AllOptionPlansMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!-- 
I~1\FVPHexeD5678YReqi>XUI~\FVPYwivc444c555cT{h>6<HE<4GG1FH<:18F651FFH;1:=H5=G<6G96I -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit>
<xbrli:unit id="GBP_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_30-Jun-2012">MGT CAPITAL INVESTMENTS INC</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_30-Jun-2012">0001001601</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_30-Jun-2012">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_30-Jun-2012">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_6ME_30-Jun-2012">mgt</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_14-Aug-2012" unitRef="shares" decimals="0">2445187</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_6ME_30-Jun-2012">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_6ME_30-Jun-2012">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_30-Jun-2012">2012-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_30-Jun-2012">Q2</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_30-Jun-2012">2012</dei:DocumentFiscalYearFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">8434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3704000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">581000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">3123000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">5658000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">2434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtMember" unitRef="USD" decimals="-3">3223000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">3224000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">2434000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="-3">5704000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">84000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">14000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">327000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">75000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:InventoryNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">89000</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">56000</us-gaap:InventoryNet>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">4204000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">5803000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">28000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">26000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">201000</us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">53000</us-gaap:SecurityDeposit>
<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">4433000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">8239000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">213000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">287000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">502000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">512000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">71000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:OtherLiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">32000</us-gaap:OtherLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">786000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">1343000</us-gaap:LiabilitiesCurrent>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">2000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">2000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">283240000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">287344000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-4861000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">-5831000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-280027000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">-281523000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-1646000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">-8000</us-gaap:StockholdersEquity>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">5293000</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">4361000</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">3573000</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">788000</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">5293000</us-gaap:MinorityInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">3647000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">4353000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">283240000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">287344000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-4861000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-5831000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-280027000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-281523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">-1646000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">-8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">5293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">4361000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">4433000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">8239000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Jun-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">75000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">75000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">2108187</us-gaap:CommonStockSharesIssued>

<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">2108187</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">2105187</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">121000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">121000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">164000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">164000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-7000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">13000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">-20000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">170000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">170000</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:GrossProfit>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">2214000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">4412000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">1091000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">1904000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">324000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">764000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">32000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">73000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">2538000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">5176000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">1123000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">1977000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-2417000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">-421000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">-1996000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-5012000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">-750000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">-4262000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1130000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">-69000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">-562000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">-472000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">-27000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1807000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">-69000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">-768000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">-956000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">-14000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">11000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">113000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-99000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-101000</us-gaap:OtherNonoperatingIncomeExpense>
<mgt:GainOnSaleOfMoneygate contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">81000</mgt:GainOnSaleOfMoneygate>
<mgt:GainOnSaleOfMoneygate contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:GainOnSaleOfMoneygate>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">11000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">32000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-23000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-25000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-2406000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-4899000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1229000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1908000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-51000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-51000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:ProfitLoss contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-2355000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-4848000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1229000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1908000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-1496000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">-1496000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">-412000</us-gaap:ProfitLoss>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-905000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-1906000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-203000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-412000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">-381000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">-31000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-1450000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-2942000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1026000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1496000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">54000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">404000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">68000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">36000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">36000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-2301000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-4444000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1233000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1840000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-888000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-1742000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-204000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-380000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">-1413000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-2702000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-1029000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1460000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_30-Jun-2011" unitRef="USD_per_Share" decimals="2">-1.24</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_30-Jun-2011" unitRef="USD_per_Share" decimals="2">-2.51</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_30-Jun-2012" unitRef="USD_per_Share" decimals="2">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_30-Jun-2012" unitRef="USD_per_Share" decimals="2">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
<mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="Context_3ME_30-Jun-2011" unitRef="shares" decimals="0">1171518</mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
<mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="Context_6ME_30-Jun-2011" unitRef="shares" decimals="0">1171518</mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
<mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="Context_3ME_30-Jun-2012" unitRef="shares" decimals="0">2105187</mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
<mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">2106763</mgt:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">2109</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">2105</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:SharesOutstanding>
<mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-5000</mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit>
<mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-5000</mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit>
<mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">-5000</mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit>
<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">-4</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2392000</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-1006000</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">1386000</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">-1386000</us-gaap:MinorityInterestDecreaseFromRedemptions>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">32000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">15000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">15000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:Depreciation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">42000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">15000</us-gaap:Depreciation>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">147000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">126000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">21000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">191000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">167000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2011_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">24000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2011_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">74000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">197000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">197000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">229000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="-3">222000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2012_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">7000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">15000</us-gaap:ShareBasedCompensation>
<mgt:GainOnSaleOfLoanReceivableRelatedParty contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">81000</mgt:GainOnSaleOfLoanReceivableRelatedParty>
<mgt:GainOnSaleOfLoanReceivableRelatedParty contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:GainOnSaleOfLoanReceivableRelatedParty>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">176000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-72000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<mgt:IncreaseDecreaseInOtherReceivableRelatedParty contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-47000</mgt:IncreaseDecreaseInOtherReceivableRelatedParty>
<mgt:IncreaseDecreaseInOtherReceivableRelatedParty contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:IncreaseDecreaseInOtherReceivableRelatedParty>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">337000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-36000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
<us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">140000</us-gaap:IncreaseDecreaseInSecurityDeposits>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">197000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">71000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-154000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-5000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-23000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-5123000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1037000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-1100000</us-gaap:RepaymentsOfRelatedPartyDebt>
<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:RepaymentsOfRelatedPartyDebt>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="GBP" decimals="-3">250000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
<us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="USD" decimals="-3">401000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
<us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">401000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
<us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
<mgt:ReceiptsOfDeferredConsiderationForSaleOfAssetsFromDiscontinuedOperation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">370000</mgt:ReceiptsOfDeferredConsiderationForSaleOfAssetsFromDiscontinuedOperation>
<mgt:ReceiptsOfDeferredConsiderationForSaleOfAssetsFromDiscontinuedOperation contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:ReceiptsOfDeferredConsiderationForSaleOfAssetsFromDiscontinuedOperation>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">1981000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-212000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<mgt:PaymentsForReverseOrForwardStockSplit contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:PaymentsForReverseOrForwardStockSplit>
<mgt:PaymentsForReverseOrForwardStockSplit contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">5000</mgt:PaymentsForReverseOrForwardStockSplit>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">3123000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">412000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">80000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-2730000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">1954000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;div&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 1: Organization, basis of presentation and liquidity&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 15pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying unaudited condensed consolidated financial statements of MGT Capital Investments, Inc. (&amp;#8220;MGT&amp;#8221;, &amp;#8220;the Company&amp;#8221;, &amp;#8220;the Group&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, have been included. Operating results for the six months ended June 30, 2012, are not necessarily indicative of the results that may be expected for any subsequent quarter or for the year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated. U.S. Dollars are denoted herein by &amp;#8220;USD&amp;#8221; and the UK Pound Sterling is denoted herein by &amp;#8220;&amp;#163;&amp;#8221; or &amp;#8220;GBP.&amp;#8221;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;We have a wholly-owned subsidiary MGT Capital Investments (UK) Limited and a majority-owned subsidiary MGT Gaming, Inc. (&amp;#8220;MGT Gaming&amp;#8221;), a company in which we acquired a majority interest on June 1, 2012. In addition, we also have a majority interest in Medicsight Ltd., including its wholly-owned subsidiaries (&amp;#8220;Medicsight&amp;#8221;).&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&amp;#8226;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;MGT Gaming holds certain intellectual property patents focused in the casino gaming sector. The Company holds 55% of the issued share capital of MGT Gaming. MGT Gaming is privately held by MGT and J&amp;amp;S Gaming, Inc.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&amp;#8226;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;Medicsight is a medical technology company focusing on medical imaging software development and medical hardware devices. The Company developed and is commercializing Computer-Aided Detection (&amp;#8220;CAD&amp;#8221;) applications that analyze Computer Tomography (&amp;#8220;CT&amp;#8221;) scans to assist radiologists in the early detection and measurement of colorectal polyps. The CAD software received a CE Mark in 2009, which allows for sales in the European Union. In 2011, Medicsight&amp;#8217;s software also received clearance from the U.S. Food and Drug Administration. Revenue is presently limited as Medicsight attempts to commercialize its recent U.S. approval. The Company has also developed an automated CO &lt;sub&gt;2&lt;/sub&gt; medical inflation device and associated disposable tubing (MedicCO &lt;sub&gt;2&lt;/sub&gt; LON) that is being commercialized via a global distributor. The Company continues to explore all strategic alternatives with respect to its majority interest in Medicsight Limited, including sale or license of its global patent portfolio. As of June 30, 2012, the Company holds 318 shares (66.5%) of the 478 issued share capital of Medicsight. Medicsight was previously listed on the AIM market of the London Stock Exchange until September 2011, when its shares were cancelled based upon a duly passed shareholder resolution and Medicsight became private.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&amp;#8226;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;On March 21, 2012, MGT affected a reverse split, immediately followed by a forward split. At our March 20, 2012 Special Meeting of Stockholders, the Company&amp;#8217;s stockholders approved the proposal to amend the Company&amp;#8217;s Certificate of Incorporation to effect a Reverse/Forward Split of the Company&amp;#8217;s Common Stock, $0.01 par value per share at an exchange ratio of 1 for 500 shares of the Company&amp;#8217;s outstanding Common Stock, immediately followed by a forward split of the Company&amp;#8217;s outstanding Common Stock, at an exchange ratio of 15 for 1 shares of the Company&amp;#8217;s outstanding Common Stock. The amendment did not change the par value per share or the number of authorized shares of Common Stock. As a result of the Reverse Split, stockholders holding fewer than 500 shares of Common Stock, at the time of the reversal, received a cash payment instead of fractional shares and no longer had an interest in the Company. All Share and per share amounts have been retrospectively adjusted for all periods presented to give effect to the Reverse/Forward Split.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;div style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/div&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&amp;#8226;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;On March 26, 2012, at Medicsight&amp;#8217;s General Meeting, stockholders approved a resolution to Reverse Split the Company&amp;#8217;s existing ordinary shares of &amp;#163;0.05 par value per share into 1 new ordinary share of &amp;#163;16,250 par value per share and for MGT to acquire all New Ordinary Shares representing
 the fractions of shares left over following the Reverse Split. The exchange ratio for the Reverse Split was 1 for 325,000. As a result of the Reverse Split, stockholders holding fewer than 325,000 shares were cancelled and not entitled to a cash payment for fractional shares.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 15pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has incurred significant operating losses since inception and continues to generate losses from operations. As a result, the Company has generated negative cash flows from operations and has an accumulated deficit of $281,523 at June 30, 2012. The Company is operating in a developing industry based on new technology and its primary source of funds to date has been through the issuance of securities. While the Company is optimistic and believes appropriate actions are being taken, there can be no assurance that management&amp;#8217;s efforts will be successful or that the products the Company develops and markets will be accepted by consumers.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;At June 30, 2012, MGT&amp;#8217;s and Medicsight&amp;#8217;s cash and cash equivalents were $3,223 and $2,435, respectively. Management believes that the current level of working capital will be sufficient to allow the Company to maintain its operations into September 2013.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 2: Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Principles of consolidation&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The condensed consolidated financial statements include the accounts of our Company plus wholly-owned subsidiaries and our majority owned subsidiaries, Medicsight and MGT Gaming. The functional currency of Medicsight is its local currency, GBP. All intercompany transactions and balances have been eliminated. All foreign currency translation gains and losses arising on consolidation were recorded in stockholders&amp;#8217; equity as a component of accumulated other comprehensive income/(loss). Non-controlling interest represents the minority equity investment in any of the MGT group of companies, plus the minorities&amp;#8217; share of the net operating result and other components of equity relating to the non-controlling interest.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company considers investments with original maturities of three months or less to be cash equivalents.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&lt;i&gt;Medicsight&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company recognizes revenue when it is realized or realizable and earned. We consider revenue realized or realizable and earned when there is persuasive evidence of an arrangement and that the product has been shipped or the services have been provided to the customer, the sales price is fixed or determinable and collectability is probable.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Software&amp;#160;&amp;#8212;&amp;#160;License fee revenue is derived from the licensing of computer software. Maintenance revenue is derived from software maintenance. Our software licenses are generally sold as part of an arrangement that includes maintenance and support.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: center;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company licenses software and sells maintenance contracts through visualization solution partners and original equipment manufacturers. The Company receives regular sales reporting detailing the number of licenses sold by original equipment manufacturers, value-added resellers and independent distributors (collectively, &amp;#8220;Resellers&amp;#8221;) to end users. The Company generally offers terms that require payment 30&amp;#160;&amp;#8211;&amp;#160;45 days from invoicing. Provided the Reseller: (i) assumes all risk of the purchase, (ii) has the ability and obligation to pay regardless of receiving payment from the end user, and (iii) all other revenue recognition criteria are met, license revenue from Resellers is recognized upon shipment of its product to vendors (&amp;#8220;sell-in basis&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Revenue from license fees is recognized when notification of shipment to the end user has occurred, there are no significant Company obligations with regard to implementation and the Company&amp;#8217;s services are not considered essential to the functionality of other elements of the arrangement.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Maintenance&amp;#160;&amp;#8212;&amp;#160;Revenue from maintenance and support arrangements is deferred and recognized ratably over the term of the maintenance and support arrangements.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Multiple-element arrangements&amp;#160;&amp;#8212;&amp;#160;the Company enters into arrangements with resellers that include a combination of software products, maintenance and support. For such arrangements, the Company recognizes revenue using the Multiple-Deliverable Revenue Arrangements. The Company allocates the total arrangement fee among the various elements of the arrangement based on the fair value of each of the undelivered elements. The
 fair value of maintenance and support services is established based on renewal rates.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Hardware&amp;#160;&amp;#8212;&amp;#160;Revenue is derived from the sale of our MedicCO &lt;sub&gt;2&lt;/sub&gt; LON product. This product is an automated CO &lt;sub&gt;2&lt;/sub&gt; insufflation device, and is generally sold as part of an arrangement that includes a one-year warranty. The risk of incurring warranty related expense is mitigated by the warranty contractually agreed with the supplier. The Company reviews the risk of warranty liabilities on a regular basis, and makes any and all appropriate provisions accordingly. At the present time, the Company feels that the warranty liability is insignificant and has therefore not made any provision.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;MedicCO &lt;sub&gt;2&lt;/sub&gt; LON is sold exclusively through our distribution partner Medrad, Inc. Revenue is recognized as orders are satisfied and goods are delivered to our distribution partner. The Company generally offers terms which require payments within 30&amp;#160;&amp;#8211;&amp;#160;45 days from invoicing.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Services-consulting&amp;#160;&amp;#8212;&amp;#160;Consulting revenue is earned over the period in which the Company provides the related services. The Company recognizes consulting revenue as it meets the terms of the underlying contract on the terms of the agreement.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Equity-based compensation&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company recognizes compensation expense for all equity-based payments. Under fair value recognition provisions, the Company recognizes equity-based compensation net of an estimated forfeiture rate and recognizes compensation cost only for those shares expected to vest over the requisite service period of the award.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the development of assumptions that are input into the model. These assumptions are the expected stock volatility, the risk-free interest rate, the option&amp;#8217;s expected life and the dividend yield on the underlying stock. Expected volatility is calculated based on the historical volatility of our common stock over the expected option life and other appropriate factors. Risk-free interest rates are calculated based on continuously compounded risk-free rates for the appropriate term. The dividend yield is assumed to be zero as the Company has never paid or declared any cash dividends on our common stock and does not intend to pay dividends on our common stock in the foreseeable future. The expected forfeiture rate is estimated based on historical experience.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Determining the appropriate fair value model and calculating the fair value of equity-based payment awards requires the input of the subjective assumptions described above. The assumptions used in calculating the fair value of equity-based payment awards represent management&amp;#8217;s best estimates, which involve inherent uncertainties and the application of management&amp;#8217;s judgment. As a result, if factors change and the Company uses different assumptions, our equity-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and recognize expense only for those shares expected to vest. If our actual forfeiture rate is materially different from our estimate, the equity-based compensation expense could be significantly different from what the Company has recorded in the current period.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;We account for inventory at the lower of cost (first-in, first-out) or market. Cost is determined to be purchased cost for the finished MedicCO &lt;sub&gt;2&lt;/sub&gt; LON product from the third party supplier. We perform full physical inventory counts to maintain controls and obtain accurate data. The MedicCO &lt;sub&gt;2&lt;/sub&gt; LON product is either (i) sold to our exclusive distributor or (ii) placed in an external third party secure warehouse facility and remains our property. Once the units are shipped to the distributor it is deemed that the ownership is transferred to the distributor and the goods are delivered. Reserves for slow-moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Research and development&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company incurs costs in connection with the development of software products that are intended for sale. Costs incurred prior to technological feasibility being established for the product are expensed as
 incurred. Technological feasibility is established upon completion of a detail program design or, in its absence, completion of a working model. Thereafter, all software production costs are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. Capitalized costs are amortized based on current and future revenue for each product with an annual minimum equal to the straight-line amortization over the remaining estimated economic life of the product. Amortization commences when the product is available for general release to customers.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company concluded that capitalizing such expenditures on completion of a working model was inappropriate because the Company did not incur any material software production costs and therefore expenses were all research and development costs. Our research and development costs are comprised of staff, consultancy and other costs expensed on the Medicsight products.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Property and equipment&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method on the various asset classes over their estimated useful lives, which range from two to five years. Leasehold improvements are depreciated over the term of the lease.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0;"&gt;&lt;i&gt;Foreign currency translation&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Prior to June 30, 2012, the accounts of the Company were maintained using GBP as the functional currency. Assets and liabilities were translated into U.S. dollars at period-end exchange rates, and income and expense accounts were translated at average monthly exchange rates. Net gains and losses from foreign currency translations were excluded from operating results and were accumulated as a separate component of stockholders&amp;#8217; equity. Gains and losses on foreign currency transactions are reflected in selling, general and administrative expenses in the income statement.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Effective June 30, 2012, in connection with the closing of the Medicsight UK office at quarter end June 2012 and the final transfer of all operations to the U.S., along with MGT&amp;#8217;s proceeds from the sale of&amp;#160;$3.5 million of convertible notes on June 1, 2012, the Company reassessed the functional currency designation and as a result of the aforementioned activities, determined to prospectively change the functional currency from the previous local currency, GBP to the U.S. dollar ($). Under &lt;i&gt;ASC 830-10&lt;/i&gt; when the functional currency changes from a foreign currency to the reporting currency translation adjustments for prior periods shall remain in accumulated other comprehensive income/(loss) and the translated amounts for non-monetary assets at the end of the prior period become the accounting basis for those assets in the period of the change and the subsequent periods.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Convertible instruments&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with &lt;i&gt;ASC 815 &amp;#8220;Derivatives and Hedging Activities&amp;#8221;&lt;/i&gt; . Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule, when the host instrument is deemed to be conventional as that term is described under applicable GAAP.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized using the effective interest method over the term of the related debt to their stated date of redemption.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;
 text-align: justify; text-indent: 25pt;"&gt;The Company applies the elements of &lt;i&gt;FASB ASC 740-10 &amp;#8220;Income Taxes&amp;#160;&amp;#8212;&amp;#160;overall&amp;#8221;&lt;/i&gt; regarding accounting for uncertainty in income taxes. This clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of June 30, 2012 and December 31, 2011, the Company did not have any unrecognized tax benefits. The Company does not expect that the amount of unrecognized tax benefits will significantly increase or decrease within the next twelve months. The Company&amp;#8217;s policy is to recognize interest and penalties related to tax matters in the income tax provision in the Consolidated Statements of Operations. There was no interest and penalties for the six months ended June 30, 2012 and 2011. Tax years beginning in 2009 are generally subject to examination by taxing authorities, although net operating losses from all years are subject to examinations and adjustments for at least three years following the year in which the attributes are used.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Deferred taxes are computed based on the tax liability or benefit in future years of the reversal of temporary differences in the recognition of income or deduction of expenses between financial and tax reporting purposes. The net difference, if any, between the provision for taxes and taxes currently payable is reflected in the balance sheet as deferred taxes. Deferred tax assets and/or liabilities, if any, are classified as current and non-current based on the classification of the related asset or liability for financial reporting purposes, or based on the expected reversal date for deferred taxes that are not related to an asset or liability. Valuation allowances are recorded to reduce deferred tax assets to that amount which is more likely than not to be realized.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Loss per share&lt;/i&gt;&lt;/div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is calculated by dividing the net loss attributable to common shareholders by the sum of the weighted average number of common shares outstanding plus dilutive shares.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The computation of diluted loss per share for the six months ended June 30, 2012, and 2011, excludes all options at our Medicsight subsidiary as they are anti-dilutive. For the six months ended June 30, 2012, there were 6 options excluded with a weighted average exercise price of $46,326 per share. For the six months ended June 30, 2011, there were 31 options excluded with a weighted average exercise price of $78,000 per share. The convertible Note is also excluded from dilutive loss per share, since its inclusion would be anti-dilutive due to the net loss.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Comprehensive income/(loss)&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Comprehensive income/(loss) includes net income/(loss) and items defined as other comprehensive income/(loss). Items defined as other comprehensive income/(loss), include foreign currency translation adjustments and are separately classified in the consolidated financial statements. Such items are reported in the Condensed Consolidated Statement of Operations and Comprehensive Loss.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Segment reporting&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer, chief financial officer and members of senior management. We operate in three operational segments, Medicsight Software/Devices, Medicsight Services and MGT Gaming. Certain corporate expenses are not allocated to segments. Medicsight services and MGT Gaming are new segments for the current quarter.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Deferred Financing Costs&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;In conjunction with the issuance of Senior Secured Convertible Notes on June 1, 2012, (as described in Note 9 to the Condensed Consolidated Financial Statements), the Company incurred certain financing costs, including the issuance of Common Stock. The Company accounts for deferred financing costs in accordance with ASC Topic 470, &lt;i&gt;Debt&lt;/i&gt; (&amp;#8220;ASC 470&amp;#8221;). Deferred financing costs are amortized through periodic charges to other non-operating expenses over the 18 months term of the related financial instrument using the effective interest method.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman,
 times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Estimates of future cash flows and timing of events for evaluating long-lived assets for impairment are based upon management&amp;#8217;s judgment. If any of our intangible or long-lived assets are considered to be impaired, the amount of impairment to be recognized is the excess of the carrying amount of the assets over its fair value. Applicable long-lived assets are amortized or depreciated over the shorter of their estimated useful lives, the estimated period that the assets will generate revenue, or the statutory or contractual term in the case of patents. Estimates of useful lives and periods of expected revenue generation are reviewed periodically for appropriateness and are based upon management&amp;#8217;s judgment. Goodwill and other assets are not amortized.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Amortization expense was $17 for the three and six months ended June 30, 2012, respectively. Based on the Company&amp;#8217;s amortizable intangible assets as of June 30, 2012, amortization expense is expected to be approximately $102 for the remainder of 2012 and be approximately $204 for each of the next five fiscal years.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Beneficial conversion features&lt;/i&gt;&lt;/div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;From time to time, the Company may issue convertible notes that may have conversion prices that create an embedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in-capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 3: Divestment of investments&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On March 31, 2010, the Company sold its stock in Medicexchange and various non-core investments for consideration of &amp;#163;750 ($1,136). This consideration was deferred and was paid in installments, with the final installment of &amp;#163;244 ($370) paid in March 2011.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;In Fiscal 2009, we purchased 49% of the share capital of Moneygate Group Limited (&amp;#8220;Moneygate&amp;#8221;), which was accounted for under the equity method. In March 2011, we sold our entire interest in Moneygate for total consideration of &amp;#163;250 ($401), resulting in a gain on sale of &amp;#163;51 ($81).&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
<us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 4: Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;We invest our cash in short-term deposits with major banks. As of June 30, 2012, we held $5,658 of cash and cash equivalents.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Cash and cash equivalents consist of cash and temporary investments with original maturities of 90 days or less when purchased.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Concentrations&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;We maintain cash and cash equivalents with certain major financial institutions, in the US, Europe and the UK. As of June 30, 2012, our cash balance was $5,658. Of the total cash balance, $3,271 was covered by federal depository insurance in the US and $2,387 was uninsured in foreign institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
<mgt:LoansReceivableRelatedPartyTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 5: Loans receivable &amp;#8212; related party&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Dunamis Capital&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On September 6, 2010, Medicsight made a short-term loan of $1,100 (&amp;#163;711) to Dunamis Capital (&amp;#8220;Dunamis&amp;#8221;) repayable by December 31, 2010, along with $36 (&amp;#163;23) of interest. Dunamis paid back the principal of $1,100 (&amp;#163;711) and interest of $48 (&amp;#163;31) on February 6, 2011 and February 10, 2011 respectively. Dunamis had provided the assets of the business as collateral against the loan made by Medicsight. Dunamis was considered a related party, as two former directors of Medicsight were also directors of Dunamis Capital (Note 13).&lt;/p&gt;</mgt:LoansReceivableRelatedPartyTextBlock>
<us-gaap:InventoryDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 6: Inventory&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;At June 30, 2012 and December 31, 2011, MedicCO &lt;sub&gt;2&lt;/sub&gt; LON Limited, a subsidiary of Medicsight, held finished goods inventory comprised of insufflation devices and administration kits totaling $56 and $89, respectively.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
<mgt:InterstAndOtherIncomeOrExpenseTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 12: Interest and other income/(expense)&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company&amp;#8217;s interest and other (expense)/income were as follows:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Three&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Six&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 48%;" nowrap="nowrap"&gt;Interest (expense)/income&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;(23&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;(23&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;32&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Other (expense)/income&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(2&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Total&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(23&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(25&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</mgt:InterstAndOtherIncomeOrExpenseTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 11: Stock incentive plan and share-based compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Stock incentive plan&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company&amp;#8217;s board of directors established the 2012 Stock Incentive Plan (the &amp;#8220;Plan&amp;#8221;) on April 15, 2012, and the Company&amp;#8217;s shareholders ratified the Plan at the annual meeting of the Company&amp;#8217;s stockholders on May 30, 2012. 415,000 shares of Common Stock were reserved to grant Options, Stock Awards and Performance Shares (collectively the &amp;#8220;Awards&amp;#8221;) to &amp;#8220;Participants&amp;#8221; under the Plan. The Plan is administered by the board of directors or the Compensation Committee of the board of directors, which determines the individuals to whom awards shall be granted as well as the type, terms and conditions of each award, the option price and the duration of each award.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Options granted under the Plan vest as determined by the Company&amp;#8217;s Compensation and Nominations Committee and expire over varying terms, but not more than seven (7) years from date of grant. In the case of an Incentive Stock Option that is granted to a 10% shareholder on the date of grant, such Option shall not be exercisable after the expiration of five (5) years from the date of grant.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Issuance of restricted shares&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;At the June 25, 2012 board meeting, the members of the Compensation and Nominations Committee approved the grant of 232,000 restricted shares of MGT common stock under the Plan, with each current independent director of the board receiving 21,000 restricted shares and 190,000 shares awarded to officers and certain employees. The restricted shares vest one-third each six months from date of issue. The unvested shares are subject to forfeiture if the applicable recipient is not a director, officer and/or employee of the Company at the time the restricted shares are to vest. The restricted shares were valued at their fair market value on date of grant, of which the share-based compensation expense will be recognized over their vesting period.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;At June 30, 2012 the Company accrued $12 share-based compensation expense relating to the issuance of the restricted shares. The shares were issued on August 9, 2012. No option grants were issued during the six months ended June 30, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Issuance of shares to former directors&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;At the June 25, 2012 board meeting, the members of the Compensation and Nominations Committee approved the issuance of 33,000 shares of common stock to certain of our former directors for past service on the Company&amp;#8217;s board of directors. These shares were subsequently issued on August 10, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The stock was valued at $185, using the closing market price on the date of grant. Stock-based compensation of $185 was recorded and accrued for at June 30, 2012 and the shares were issued on August 9, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Unrecognized compensation cost&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;As of June 30, 2012 there was $1,281 of total unrecognized compensation costs related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of 1.50 years.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Medicsight equity plan&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Following Medicsight&amp;#8217;s general meeting on March 26, 2012 (Note 1), a shareholder resolution approving the Reverse Split of 1-for-325,000 of the Company&amp;#8217;s existing ordinary shares of &amp;#163;0.05 par value into one new ordinary share was duly passed. As a result of the reverse split, option holders under certain existing share option plans are no longer entitled to options under those plans as option holders&amp;#8217; share entitlement is now less than one as a result of the Reverse Split. Following the share reversal, the Company cancelled with immediate effect all redundant option plans with the exception of Plan J. All previously unrecognized stock based compensation expense was accelerated.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Medicsight has the following Stock Option
 Plan:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Plan J&amp;#160;&amp;#8212;&amp;#160;on May 14, 2009, we approved and subsequently granted options for 24 shares under stock option plan &amp;#8220;J&amp;#8221;. Options under this plan vest in equal one-sixths for each six months that employees have been employed for 6, 12, 18, 24, 30 and 36 months from the grant date. At June 30, 2012, there were 6 options outstanding and exercisable.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;No grants were issued in the six months ended June 30, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The following table summarizes stock option activity for the six months ended June 30, 2012, under all option plans:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 25pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Outstanding&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Exercisable&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number of &lt;br /&gt;shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Weighted-average &lt;br /&gt;exercise price&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number of &lt;br /&gt;shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Weighted-average &lt;br /&gt;exercise price&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 40%; text-indent: -0.1in; padding-left: 0.1in;" nowrap="nowrap"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;&amp;#163;35,700&amp;#160;($58,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;&amp;#163;35,700&amp;#160;($58,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt; padding-bottom: 1pt;"&gt;Forfeited/Cancelled&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;(5&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;&amp;#163;19,500&amp;#160;($30,917&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom:
 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt;"&gt;Outstanding at June 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid; padding-right: 0; padding-left: 0; text-indent: 0;" nowrap="nowrap"&gt;&amp;#163;$29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;The following is a summary of the status of stock options outstanding at June 30, 2012:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="10" nowrap="nowrap"&gt;Outstanding&amp;#160;options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Exercisable&amp;#160;options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Remaining &lt;br /&gt;contractual &lt;br /&gt;life &lt;br /&gt;(years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Average &lt;br /&gt;exercise&amp;#160;price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Average &lt;br /&gt;exercise&amp;#160;price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 35%; text-align: left;" nowrap="nowrap"&gt;Medicsight Plan J&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6.9&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On November 30, 2010, David Sumner, Chairman of Medicsight Limited, resigned from his position within the group. Immediately after his resignation, a two-year consultancy agreement was signed whereby Mr. Sumner would continue to assist the group in its commercial needs. As part of this agreement, Mr. Sumner was to continue to vest in his existing Medicsight Plan J options throughout the consultancy period. A modification of the 6 existing options has been accounted for, and is not considered to be material to the overall financial statements. The Company is no longer receiving services under this consulting agreement. As such, all expenses and related Stock-based compensation were accelerated at December 31, 2011.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company has recorded the following amounts related to its share-based compensation expense in the accompanying Condensed Consolidated Statements of Operations:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td
 nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Three months ended June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Six months ended June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 48%; text-align: left;" nowrap="nowrap"&gt;Selling, general and administrative&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;197&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;126&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;222&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;167&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Research and development&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;21&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;7&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 0.12in;"&gt;Total&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;197&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;147&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;229&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;191&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Of the Stock-based expense for the six months ended June 30, 2012 and 2011, $15 and $74 was allocated to non-controlling interest.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The aggregate intrinsic value for options outstanding and exercisable at June 30, 2012 and 2011, was $nil.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: center;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 13: Related party transactions&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Moneygate Group&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;In Fiscal 2009, we purchased 49% of the share capital of Moneygate. On acquisition we provided loan facilities of &amp;#163;250 ($387) for working capital and &amp;#163;2,000 ($3,094) for acquisitions and subsequently entered into various transactions with Moneygate and other non-related parties.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Through its disposal in March 2011, Moneygate was a related party as the Company had significant influence over its operations as a result of representation on Moneygate&amp;#8217;s board of directors. Due to this significant influence, we accounted for it under the equity method. In March 2011, we sold our entire interest in Moneygate to Committed for total consideration of &amp;#163;250 ($401), resulting in a gain on sale of &amp;#163;51 ($81).&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Dunamis&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Allan Rowley, former Chief Executive Officer and former Chief Financial Officer of MGT and former Chief Executive Officer of Medicsight, along with David Sumner, former Chairman of Medicsight, are both directors of Dunamis. Dunamis is a United Arab Emirates (&amp;#8220;UAE&amp;#8221;) registered company regulated by the Dubai Financial Services Authority (&amp;#8220;DFSA&amp;#8221;). Dunamis is 100% owned by David Sumner and was set up by Mr. Sumner with Allan Rowley&amp;#8217;s financial consulting assistance, as a corporate financing and advisory firm. On September 6, 2010, Medicsight made a short-term loan of $1,100 (&amp;#163;711) to Dunamis. Dunamis paid back the principal of $1,100 (&amp;#163;711) and interest of $48 (&amp;#163;30) on February 6, 2011 and February 10, 2011, respectively.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;In February 2011, the Company, following consultation with its nominated advisor noted that as a result of Mr. Sumner&amp;#8217;s relationships with both Dunamis and Medicsight, the Loan constituted a related party transaction under Rule 13 of AIM Rules for Companies. Rule 13 requires that an AIM company must issue notification without delay as soon as the terms of a transaction with a related party are agreed. The independent directors, having consulted with the Company&amp;#8217;s nominated adviser, considered the terms of the transaction fair and reasonable insofar as shareholders were concerned. In February 2011, the Company issued a notice detailing the terms of the transaction with the related party.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;Laddcap Value Partners III LLC (&amp;#8220;Laddcap&amp;#8221;)&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On April 12, 2011, the Company entered into a Revolving Line of Credit and Security Agreement with Laddcap for up to $500 for a fifteen-month term. The Agreement encompasses a standby commitment fee of two (2%) percent of the maximum loan amount along with an eight (8%) percent interest charge on any funds drawn. Laddcap is a related party as the Managing Partner and beneficial owner of Laddcap is a 10% plus shareholder and CEO of MGT. No amounts have been drawn down against the facility as of the date of the filing of the Company&amp;#8217;s Form 10-Q for the quarterly period ended June 30, 2012. The Agreement expired in July 2012 and was not renewed by management (Note 8).&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;&lt;/i&gt;&amp;#160;&lt;/p&gt;
&lt;div style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;i&gt;D4D Limited&lt;/i&gt;&lt;/div&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;Effective July 2010, the Company entered into a service agreement with D4D Limited (&amp;#8220;D4D&amp;#8221;), a company that offers Executive Services for small and mid-cap companies. D4D is owned by Tim Paterson-Brown and Allan Rowley, and pursuant to the agreement, provided the services of Chairman, Chief Executive Officer and Chief Financial Officer of the Company at such time.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;In April 2011, the agreement with D4D was terminated and a settlement agreement between MGT and D4D, Messrs. Paterson-Brown and Rowley was executed and delivered. During the six months ended June 30, 2011, MGT and Medicsight made payments to D4D, totaling $304 and $315, respectively.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<mgt:OperatingLeasesCommitmentsAndSecurityDepositTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 14: Operating leases, commitments and security deposit&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;In 2006, we executed a 10-year agreement with Pirbright Holdings Limited, to lease office space in London, United Kingdom. Under this lease agreement, the property rent, services and related costs were approximately &amp;#163;330 ($516) per annum, paid quarterly in advance. The Company exercised its right to terminate the lease upon completion of the fifth year (August 2011) and had found an alternative UK office location with no long-term lease commitment. This commitment was on a month-to-month basis and began on August 1, 2011 with total monthly rental payments of &amp;#163;8 ($13) along with a rental deposit of &amp;#163;16 ($25). In February 2012, the Company moved to a smaller office in the same location with month-to-month rental payments of &amp;#163;2 ($4) and a rental deposit of &amp;#163;4 ($6). On April 30, 2012, we terminated our UK lease effective June 30, 2012.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;In September 2011, the Company entered into a 39-month lease agreement for office space located in Harrison, New York, terminating on November 30, 2014. Under the agreement our total rental payments over the 39-month lease period are $240, inclusive of three months of free rent and a refundable rental deposit of $39.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;A satellite office in Tokyo, Japan, was closed in January 2012, and the rental deposit of $128 was refunded to us.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;The following is a schedule of the future minimum payments required under operating leases and commitments that have initial or remaining non-cancellable terms in excess of one year:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.25in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;"&gt;Year Ending&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 87%;"&gt;2012 (remaining six months)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;33&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;67&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;2014&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;56&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;156&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;The total lease rental expense was $72 and $298 for the six months ended June 30, 2012 and 2011, respectively.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;In January 2012, the Company entered into a two-year employment agreement with an employee at a base salary of $10 per month, with potential bonus payments as outlined in the agreement. This agreement provides for a maximum severance period of 12 months in the event of termination without cause as defined in the agreement.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;On March 12, 2012, the Company entered into a one-year financial advisory and consulting agreement with a national investment-banking firm. The Agreement was cancelled in May 2012 in accordance with its terms.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;On May 11, 2012, MGT Gaming entered into a one-year consulting agreement with the president of J&amp;amp;S for service to MGT Gaming, for a fee of $5 per month. The agreement can be cancelled with 60 days prior written notice.&lt;/p&gt;</mgt:OperatingLeasesCommitmentsAndSecurityDepositTextBlock>
<us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 8: Line of credit facility&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On April 12, 2011, the Company entered into an Agreement with Laddcap for up to $500 for a fifteen-month term. The Agreement encompasses a standby commitment fee of two (2%) percent of the maximum loan amount along with an eight (8%) percent interest charge on any funds drawn. The Company has fully accrued the commitment fee of $10 and expensed $4 associated with the facility for the six months ended June 30, 2012. Laddcap is a related party as the Managing Partner and beneficial owner of LaddCap is a 10% plus shareholder and President and Chief Executive Officer of MGT. The Agreement expired in July 2012, and has not been renewed. No amounts have been drawn down against the facility as of the date of the filing of the Company&amp;#8217;s Form 10-Q for the quarterly period ended June 30, 2012.&lt;/p&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The following table summarizes stock option activity for the six months ended June 30, 2012, under all option plans:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 25pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Outstanding&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Exercisable&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number of &lt;br /&gt;shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Weighted-average &lt;br /&gt;exercise price&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number of &lt;br /&gt;shares&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Weighted-average &lt;br /&gt;exercise price&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 40%; text-indent: -0.1in; padding-left: 0.1in;" nowrap="nowrap"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;11&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;&amp;#163;35,700&amp;#160;($58,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;&amp;#163;35,700&amp;#160;($58,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 9pt;"&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 9pt; padding-bottom: 1pt;"&gt;Forfeited/Cancelled&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;(5&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;&amp;#163;19,500&amp;#160;($30,917&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt;"&gt;Outstanding at June 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid;"&gt;6&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;
 border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom: black 1pt solid; padding-right: 0; padding-left: 0; text-indent: 0;" nowrap="nowrap"&gt;&amp;#163;$29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;The following is a summary of the status of stock options outstanding at June 30, 2012:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="10" nowrap="nowrap"&gt;Outstanding&amp;#160;options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Exercisable&amp;#160;options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Remaining &lt;br /&gt;contractual &lt;br /&gt;life &lt;br /&gt;(years)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Average &lt;br /&gt;exercise&amp;#160;price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Number&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Average &lt;br /&gt;exercise&amp;#160;price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 35%; text-align: left;" nowrap="nowrap"&gt;Medicsight Plan J&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6.9&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;6&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;" nowrap="nowrap"&gt;&amp;#163;29,250&amp;#160;($46,326&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company has recorded the following amounts related to its share-based compensation expense in the accompanying Condensed Consolidated Statements of Operations:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Three months ended June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Six months ended June 30,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 48%; text-align: left;" nowrap="nowrap"&gt;Selling, general and administrative&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;197&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;126&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;222&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;167&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Research and development&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;21&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;7&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;24&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 0.12in;"&gt;Total&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;197&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;147&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;229&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;191&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 25.0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company has the following non-controlling interests:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 85%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;b&gt;MGT Gaming &lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Medicsight &lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="2"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="width: 55.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="55%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling interest at January1,2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 12.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="12%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 12.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="12%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,293&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 12.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="12%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,293&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling share of losses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(31&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(381&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;"
 valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(412&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling share of capital&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;819&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;819&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling share of stock-based expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;15&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;15&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 5;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling share of other comprehensive loss&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new
 roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;32&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;32&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 6;"&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Share consolidation of Medicsight&amp;#8217;s stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(1,386&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(1,386&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 7; mso-yfti-lastrow: yes;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-controlling interest at June30,2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;788&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,573&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,361&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;p
 style="margin: 0in; margin-bottom: .0001pt; text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
<us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 25.0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The following schedule presents the effects of changes in MGT&amp;#8217;s ownership interest in Medicsight on the equity attributable to MGT:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 85%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Six months ended&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;June 30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;June 30, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="width: 74.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="74%" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Net loss attributable to MGT Capital Investments, Inc.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(1,496&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(2,942&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Transfers (to) from the non-controlling interest:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p style="text-indent: -8.65pt;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new
 roman,times"&gt;Increase in MGT&amp;#8217;s paid in capital from sale and assignment of Medicsight&amp;#8217;s stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;21&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 5;"&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Increase in MGT&amp;#8217;s paid in capital from Medicsight Share Consolidation&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,392&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 6; mso-yfti-lastrow: yes;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p style="text-indent: -8.65pt;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Changes from the net loss attributable to MGT Capital Investments, Inc. and transfers from non-controlling interest&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;896&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(2,921&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="text-align: justify; text-indent: 0.25in; margin: 0in 0in 0pt;"&gt;The following is a schedule of the future minimum payments required under operating leases and commitments that have initial or remaining non-cancellable terms in excess of one year:&lt;/p&gt;
&lt;p style="margin: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; margin-left: 0.25in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="bottom" colspan="2"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="width: 87%; background: #ccffcc; padding: 0in;" valign="bottom" width="87%"&gt;
&lt;p class="msonormal"&gt;2012(remaining six months)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10%; background: #ccffcc; padding: 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;33&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;2013&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;67&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;2014&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;56&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4; mso-yfti-lastrow: yes;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;156&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 15pt; margin: 0in 0in 0pt;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<mgt:CommonStockParValueAtExchangeRatio contextRef="Context_As_Of_30-Jun-2012" unitRef="USD_per_Share" decimals="2">0.01</mgt:CommonStockParValueAtExchangeRatio>

<us-gaap:StockholdersEquityReverseStockSplit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember">1-for-325,000</us-gaap:StockholdersEquityReverseStockSplit>
<mgt:StockholdersEquityForwardStockSplit contextRef="Context_6ME_30-Jun-2012">15-for-1 shares</mgt:StockholdersEquityForwardStockSplit>
<mgt:NumberOfSharesHoldingByStockholdersResultOfReverseStockSplit contextRef="Context_6ME_30-Jun-2012">500</mgt:NumberOfSharesHoldingByStockholdersResultOfReverseStockSplit>
<mgt:NumberOfSharesHoldingByStockholdersResultOfReverseStockSplit contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember">325,000</mgt:NumberOfSharesHoldingByStockholdersResultOfReverseStockSplit>
<mgt:ParValuePerShareOfExistingOrdinaryShares contextRef="Context_As_Of_30-Jun-2012" unitRef="GBP_per_Share" decimals="2">0.05</mgt:ParValuePerShareOfExistingOrdinaryShares>
<mgt:ParValuePerShareOfNewOrdinaryShares contextRef="Context_As_Of_30-Jun-2012" unitRef="GBP_per_Share" decimals="0">16250</mgt:ParValuePerShareOfNewOrdinaryShares>
<mgt:NumberOfSharesHoldingByParentResultOfReverseStockSplit contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">318</mgt:NumberOfSharesHoldingByParentResultOfReverseStockSplit>
<mgt:PercentageOfNumberOfSharesHoldingByParentResultOfIssuedShareCapital contextRef="Context_As_Of_30-Jun-2012" unitRef="pure" decimals="3">0.665</mgt:PercentageOfNumberOfSharesHoldingByParentResultOfIssuedShareCapital>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">2105187</us-gaap:CommonStockSharesIssued>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_30-Jun-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="shares" decimals="0">31</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_30-Jun-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="shares" decimals="0">6</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<mgt:StockOptionsWeightedAveragePricePerShare contextRef="Context_6ME_30-Jun-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="USD" decimals="-3">78000000</mgt:StockOptionsWeightedAveragePricePerShare>
<mgt:StockOptionsWeightedAveragePricePerShare contextRef="Context_6ME_30-Jun-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsMember" unitRef="USD" decimals="-3">46326000</mgt:StockOptionsWeightedAveragePricePerShare>
<mgt:ProceedsFromSaleOfStockAndVariousNoncoreInvestmentsForConsideration contextRef="Context_3ME_31-Mar-2010" unitRef="GBP" decimals="-3">750000</mgt:ProceedsFromSaleOfStockAndVariousNoncoreInvestmentsForConsideration>
<mgt:ProceedsFromSaleOfStockAndVariousNoncoreInvestmentsForConsideration contextRef="Context_3ME_31-Mar-2010" unitRef="USD" decimals="-3">-1136000</mgt:ProceedsFromSaleOfStockAndVariousNoncoreInvestmentsForConsideration>
<us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">370000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
<us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="GBP" decimals="-3">244000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="pure" decimals="2">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="GBP" decimals="-3">51000</us-gaap:GainLossOnSaleOfEquityInvestments>

<us-gaap:DueFromRelatedPartiesCurrent contextRef="Context_As_Of_31-Dec-2010_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="USD" decimals="-3">1100000</us-gaap:DueFromRelatedPartiesCurrent>
<us-gaap:DueFromRelatedPartiesCurrent contextRef="Context_As_Of_31-Dec-2010_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="GBP" decimals="-3">711000</us-gaap:DueFromRelatedPartiesCurrent>
<us-gaap:InterestReceivableCurrent contextRef="Context_As_Of_31-Dec-2010_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="USD" decimals="-3">36000</us-gaap:InterestReceivableCurrent>
<us-gaap:InterestReceivableCurrent contextRef="Context_As_Of_31-Dec-2010_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="GBP" decimals="-3">23000</us-gaap:InterestReceivableCurrent>

<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="USD" decimals="-3">1100000</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="GBP" decimals="-3">711000</us-gaap:ProceedsFromRelatedPartyDebt>

<us-gaap:InterestAndFeeIncomeLoansAndLeases contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="GBP" decimals="-3">31000</us-gaap:InterestAndFeeIncomeLoansAndLeases>
<mgt:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandcancelledinperiodweightedaverageexerciseprice contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="USD_per_Share" decimals="0">30917</mgt:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandcancelledinperiodweightedaverageexerciseprice>
<mgt:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandcancelledinperiodweightedaverageexerciseprice contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="GBP_per_Share" decimals="0">19500</mgt:Sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandcancelledinperiodweightedaverageexerciseprice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="shares" decimals="0">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_StockOptionPlanJMember" unitRef="shares" decimals="0">24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">-5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="USD_per_Share" decimals="0">46326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="GBP_per_Share" decimals="0">29250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="USD_per_Share" decimals="0">58500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="GBP_per_Share" decimals="0">35700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="USD_per_Share" decimals="0">46326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="GBP_per_Share" decimals="0">29250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="shares" decimals="0">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="shares" decimals="0">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="USD_per_Share" decimals="0">46326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember" unitRef="GBP_per_Share" decimals="0">29250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="USD_per_Share" decimals="0">58500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_PlanNameAxis_AllOptionPlansMember" unitRef="GBP_per_Share" decimals="0">35700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="USD_per_Share" decimals="0">46326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30-Jun-2012_PlanNameAxis_AllOptionPlansMember" unitRef="GBP_per_Share" decimals="0">29250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_30-Jun-2012_PlanNameAxis_MedicsightPlanJMember">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">32000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">32000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-1386000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">-1386000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
<us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet>
<us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">2392000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet>
<us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-2921000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
<us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">896000</us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet>
<mgt:ProvidedLoanFacilitiesForWorkingCapital contextRef="Context_FYE_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="USD" decimals="-3">387000</mgt:ProvidedLoanFacilitiesForWorkingCapital>
<mgt:ProvidedLoanFacilitiesForWorkingCapital contextRef="Context_FYE_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="GBP" decimals="-3">250000</mgt:ProvidedLoanFacilitiesForWorkingCapital>
<mgt:ProvidedLoanFacilitiesForAcquisitions contextRef="Context_FYE_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="USD" decimals="-3">3094000</mgt:ProvidedLoanFacilitiesForAcquisitions>
<mgt:ProvidedLoanFacilitiesForAcquisitions contextRef="Context_FYE_31-Dec-2009_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="GBP" decimals="-3">2000000</mgt:ProvidedLoanFacilitiesForAcquisitions>
<mgt:PercentageOfOwnedByRelatedParty contextRef="Context_As_Of_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="pure" decimals="4">1.0000</mgt:PercentageOfOwnedByRelatedParty>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="Context_As_Of_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="USD" decimals="-3">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="Context_3ME_30-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="pure" decimals="2">0.02</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>


<us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="Context_3ME_31-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="pure" decimals="2">0.08</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">33000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">67000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">56000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">156000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<mgt:OperatingLeasesPropertyRentServicesAndRelatedCosts contextRef="Context_FYE_31-Dec-2006" unitRef="USD" decimals="-3">516000</mgt:OperatingLeasesPropertyRentServicesAndRelatedCosts>
<mgt:OperatingLeasesPropertyRentServicesAndRelatedCosts contextRef="Context_FYE_31-Dec-2006" unitRef="GBP" decimals="-3">330000</mgt:OperatingLeasesPropertyRentServicesAndRelatedCosts>
<mgt:OperatingLeasesMonthltyRentalPayments contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">4000</mgt:OperatingLeasesMonthltyRentalPayments>
<mgt:OperatingLeasesMonthltyRentalPayments contextRef="Context_6ME_30-Jun-2012" unitRef="GBP" decimals="-3">2000</mgt:OperatingLeasesMonthltyRentalPayments>
<mgt:OperatingLeasesRentalDeposit contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">6000</mgt:OperatingLeasesRentalDeposit>
<mgt:OperatingLeasesRentalDeposit contextRef="Context_6ME_30-Jun-2012" unitRef="GBP" decimals="-3">4000</mgt:OperatingLeasesRentalDeposit>
<mgt:OperatingLeasesRentalDepositRefunded contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">128000</mgt:OperatingLeasesRentalDepositRefunded>
<us-gaap:LeaseAndRentalExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">298000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">72000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="Context_As_Of_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="pure" decimals="2">0.08</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>

<mgt:LineOfCreditFacilityExpenses contextRef="Context_6ME_30-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="USD" decimals="-3">4000</mgt:LineOfCreditFacilityExpenses>
<mgt:PercentageOfBeneficialOwned contextRef="Context_6ME_30-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="pure" decimals="4">0.1000</mgt:PercentageOfBeneficialOwned>
<mgt:AmortizationOfConvertibleNoteDiscount contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:AmortizationOfConvertibleNoteDiscount>
<mgt:AmortizationOfConvertibleNoteDiscount contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">43000</mgt:AmortizationOfConvertibleNoteDiscount>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">555000</us-gaap:DeferredFinanceCostsNet>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31-Dec-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">1802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">1802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<mgt:AssignmentOfMedicsightsStock contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-4000</mgt:AssignmentOfMedicsightsStock>
<mgt:AssignmentOfMedicsightsStock contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:AssignmentOfMedicsightsStock>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">17000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">17000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">33000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">33000</us-gaap:AmortizationOfFinancingCosts>
<mgt:IntangibleAssetsPurchased contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:IntangibleAssetsPurchased>
<mgt:IntangibleAssetsPurchased contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-200000</mgt:IntangibleAssetsPurchased>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="Context_As_Of_25-Jun-2012_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="-3">12000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">512000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="Context_As_Of_30-Jun-2012_AwardTypeAxis_FarmerDirectorMember" unitRef="USD" decimals="-3">185000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<us-gaap:ConvertibleDebtNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:ConvertibleDebtNoncurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">2543000</us-gaap:ConvertibleDebtNoncurrent>
<mgt:ReceiptsFromSaleOfMedicsightsStock contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">-110000</mgt:ReceiptsFromSaleOfMedicsightsStock>
<mgt:ReceiptsFromSaleOfMedicsightsStock contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:ReceiptsFromSaleOfMedicsightsStock>
<mgt:ProceedsFromIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:ProceedsFromIssuanceOfConvertibleNote>
<mgt:ProceedsFromIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-3500000</mgt:ProceedsFromIssuanceOfConvertibleNote>
<mgt:PaymentsForConvertibleNoteIssuanceCosts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:PaymentsForConvertibleNoteIssuanceCosts>
<mgt:PaymentsForConvertibleNoteIssuanceCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-372000</mgt:PaymentsForConvertibleNoteIssuanceCosts>
<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">786000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">3886000</us-gaap:Liabilities>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Jun-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CashFDICInsuredAmount contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">3271000</us-gaap:CashFDICInsuredAmount>
<us-gaap:CashUninsuredAmount contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">2387000</us-gaap:CashUninsuredAmount>
<mgt:AmortizationDescription contextRef="Context_6ME_30-Jun-2012">Amortization expense is expected to be approximately $102 for the remainder of 2012 and be approximately $204 for each of the next five fiscal years.</mgt:AmortizationDescription>
<mgt:ProceedsFromSaleOfConvertableNotes contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtMember" unitRef="USD" decimals="-5">3500000</mgt:ProceedsFromSaleOfConvertableNotes>
<us-gaap:AdjustmentForAmortization contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">17000</us-gaap:AdjustmentForAmortization>
<mgt:InterestIncomeExpenseNonoperating contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">11000</mgt:InterestIncomeExpenseNonoperating>
<mgt:InterestIncomeExpenseNonoperating contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">32000</mgt:InterestIncomeExpenseNonoperating>
<mgt:InterestIncomeExpenseNonoperating contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-23000</mgt:InterestIncomeExpenseNonoperating>
<mgt:InterestIncomeExpenseNonoperating contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-23000</mgt:InterestIncomeExpenseNonoperating>
<us-gaap:TechnologyServicesRevenue contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">217000</us-gaap:TechnologyServicesRevenue>
<us-gaap:TechnologyServicesRevenue contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">264000</us-gaap:TechnologyServicesRevenue>
<us-gaap:TechnologyServicesRevenue contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">13000</us-gaap:TechnologyServicesRevenue>
<us-gaap:TechnologyServicesRevenue contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">206000</us-gaap:TechnologyServicesRevenue>
<us-gaap:SalesRevenueServicesGross contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueServicesGross>
<us-gaap:SalesRevenueServicesGross contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueServicesGross>
<us-gaap:SalesRevenueServicesGross contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">43000</us-gaap:SalesRevenueServicesGross>
<us-gaap:SalesRevenueServicesGross contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">63000</us-gaap:SalesRevenueServicesGross>
<us-gaap:TechnologyServicesCosts contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">96000</us-gaap:TechnologyServicesCosts>
<us-gaap:TechnologyServicesCosts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">100000</us-gaap:TechnologyServicesCosts>
<us-gaap:TechnologyServicesCosts contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:TechnologyServicesCosts>
<us-gaap:TechnologyServicesCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">36000</us-gaap:TechnologyServicesCosts>
<us-gaap:OtherCostOfServices contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:OtherCostOfServices>
<us-gaap:OtherCostOfServices contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:OtherCostOfServices>
<us-gaap:OtherCostOfServices contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">63000</us-gaap:OtherCostOfServices>
<us-gaap:OtherCostOfServices contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">63000</us-gaap:OtherCostOfServices>
<mgt:IntellectualPropertyTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Note 7: Intellectual property&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 15pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 11, 2012, the Company entered into a Contribution and Sale Agreement (the &amp;#8220;Sale Agreement&amp;#8221;) with J&amp;amp;S Gaming, Inc. (&amp;#8220;J&amp;amp;S&amp;#8221;), and MGT Gaming, Inc. (&amp;#8220;MGT Gaming&amp;#8221;) for the acquisition of U.S. Patent #7,892,088, entitled &amp;#8220;Gaming Device Having a Second Separate Bonusing Event&amp;#8221; (&amp;#8220;The Patent&amp;#8221;). All terms&amp;#160;of the Sale Agreement were filed in an 8-K on May 16, 2012. The patent acquired was recorded at its estimated fair value of $1,819 at the date of acquisition.&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The intellectual property is subject to amortization and will be expensed using the straight-line method, over nine years, the remaining life of the patent. Amortization expense was $17 for both the three and six months ended June 30, 2012. The Company&amp;#8217;s future amortization expense for this intangible asset is expected to be approximately $102 for the remainder of 2012 and be approximately $204 for each of the next five fiscal years.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Pursuant to the Sale Agreement, (i) J&amp;amp;S sold certain patents to MGT Gaming in exchange for 1,000 shares (constituting 100% ownership) of MGT Gaming Common Stock, par value $0.001; (ii) the Company purchased from J&amp;amp;S 550 MGT Gaming Shares constituting 55% ownership in exchange for $200 cash and a four (4) year warrant to purchase 350,000 shares of the Company&amp;#8217;s common stock at an exercise price of $4.00 per share, subject to certain anti-dilution provisions (the &amp;#8220;Warrants&amp;#8221;); (iii) the Company and J&amp;amp;S agreed to grant rights of first refusal, &amp;#8220;tag-along&amp;#8221; and &amp;#8220;drag-along&amp;#8221; rights to one another with respect to their respective MGT Gaming Shares. As a result of an anti-dilution provision in the warrants, with respect to future stock or option grants to officers, the Company anticipates issuing 50,000 additional Warrants to J&amp;amp;S over the next 12 months. These additional warrants were included in the calculation of purchase price for the intellectual property acquisition. The fair value of the 400,000 warrants was determined to be $800 as of June 1, 2012, the warrant issuance date.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The warrants were fair-valued as of the issuance date of June 1, 2012 at $800 based upon the following Black-Scholes pricing model (&amp;#8220;BSM&amp;#8221;) assumptions; risk free rate 0.80%; expected term four (4) years; annual volatility 75.0%; exercise price $4.00; as the underlying shares had not yet been registered at the issuance date, the market price at June 1, 2012 was discounted by approximately 11% for options pricing purposes.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;For purposes of determining expected volatility, since the Company does not have representative historical data to determine volatility based upon its own information, the Company used significant judgment to identify a peer group and determine the appropriate weighting in order to estimate the volatility rate for use in the BSM. The risk-free rate for the period coincides with the expected life of the warrants and is based on the U.S. Treasury Department yield curve in effect at time of closing.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;ASC 350 &amp;#8220;Intangible Assets&lt;/i&gt; &amp;#8221;, establishes Accounting and Measurement guidance for the acquisition of the intellectual property asset from J&amp;amp;S. The Company determined that the consideration given for 55% of the patent was the best indication of the fair value of the patent, as such, the 45% of the patent contributed by the non-controlling shareholders is valued at $819.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The fair value was determined as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 87%;"&gt;Cash&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;200&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Fair value of warrants issued&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;800&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Fair value of intangible asset contributed by non-controlling interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;819&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1,819&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 15pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 25pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Additionally, the Company has the right to purchase an additional 250 MGT Gaming Shares from J&amp;amp;S in exchange for a cash payment of $1,000 and a four (4) year warrant to purchase 250,000 shares of the Company&amp;#8217;s common stock for an exercise price of the lower of (i) $6.00 per share and (ii) 110% of the closing price of the common stock on the date of issuance. This option expires on August 31, 2012 due to the qualified financing, as defined in the Agreement that the Company entered into with Hudson Bay Fund Ltd. Due to the high exercise price of this option and its very short term nature its fair value was determined to be de minimis.&lt;/p&gt;</mgt:IntellectualPropertyTextBlock>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">819000</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">819000</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">819000</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">800000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">800000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">800000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote><mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote><mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">400000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote><mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</mgt:WarrantIssuedInConnectionWithIssuanceOfConvertibleNotes>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">400000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">400000</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_ParentMember" unitRef="USD" decimals="-3">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">76000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">76000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:Revenues contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">217000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">264000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">56000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">269000</us-gaap:Revenues>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">96000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">96000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">100000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">100000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">63000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">63000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">99000</us-gaap:CostOfRevenue>

<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">36000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">63000</us-gaap:CostOfRevenue>
<us-gaap:MinorityInterestDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 10: Non-controlling interest&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The Company has the following non-controlling interests:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; text-decoration: none;"&gt;
&lt;td style="text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid; text-decoration: none;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;b style="text-decoration: none;"&gt;&lt;u style="text-decoration: none;"&gt;MGT Gaming &lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom: black 1pt solid; text-decoration: none; vertical-align: bottom;" colspan="2"&gt;&lt;b style="text-decoration: none;"&gt;&lt;u style="text-decoration: none;"&gt;Medicsight &lt;/u&gt;&lt;/b&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid; text-decoration: none;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold; text-decoration: none;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 55%;"&gt;Non-controlling interest at January 1, 2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;5,293&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;5,293&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Non-controlling share of losses&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(31&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(381&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(412&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Non-controlling share of capital&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;819&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;819&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Non-controlling share of stock-based expense&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Non-controlling share of other comprehensive loss&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;32&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Share consolidation of Medicsight&amp;#8217;s stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,386&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,386&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Non-controlling interest at June 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;788&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;3,573&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4,361&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The following schedule presents the effects of changes in MGT&amp;#8217;s ownership interest in Medicsight on the equity attributable to MGT:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse;
 font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Six months ended&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;June 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;June 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 74%; text-align: left;" nowrap="nowrap"&gt;Net loss attributable to MGT Capital Investments, Inc.&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;(1,496&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;(2,942&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;Transfers (to) from the non-controlling interest:&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; text-indent: -0.12in; padding-left: 0.12in;"&gt;Increase in MGT&amp;#8217;s paid in capital from sale and assignment of Medicsight&amp;#8217;s stock&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Increase in MGT&amp;#8217;s paid in capital from Medicsight Share Consolidation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,392&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left; text-indent: -0.12in; padding-left: 0.12in;"&gt;Changes from the net loss attributable to MGT Capital Investments, Inc. and transfers from non-controlling interest&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;896&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(2,921&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;In January 2012, the Company purchased 1 share of Medicsight ordinary shares from a shareholder for consideration of $0.01.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On June 1, 2012 the Company purchased 550 shares in MGT Gaming (Note 7).&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
<mgt:PercentageOfStockholderIncentiveStockOptionGrantedOnDateOfGrant contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="0">10</mgt:PercentageOfStockholderIncentiveStockOptionGrantedOnDateOfGrant>
<mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesApprovedToGrantOfGrant contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">232000</mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesApprovedToGrantOfGrant>
<mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesIssued contextRef="Context_6ME_30-Jun-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_OfficersAndCertainEmployeesMember" unitRef="shares" decimals="0">190000</mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesIssued>
<mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesIssued contextRef="Context_6ME_30-Jun-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_EachCurrentIndependentDirectorOfBoardMember" unitRef="shares" decimals="0">21000</mgt:ShareBasedCompensationArrangementByShareBasedPaymentRestrictedSharesIssued>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_30-Jun-2012" unitRef="shares" decimals="0">415000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_25-Jun-2012_AwardTypeAxis_FarmerDirectorMember" unitRef="shares" decimals="0">33000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">1281000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_6ME_30-Jun-2012">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 15: Segment reporting&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer, chief financial officer and members of senior management. We operate in three operational segments, Medicsight Software/Devices, Medicsight Services and MGT Gaming. Certain corporate expenses are not allocated to segments.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in;"&gt;The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 2). We evaluate performance of our operating segments based on revenue and operating (loss). Segment information for the three and six months ended June 30, 2012 and June 30, 2011 are as follows:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Medicsight&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap"&gt;Unallocated&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Software/&lt;br /&gt;Devices&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Services&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;MGT&lt;br /&gt;Gaming&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;corporate/&lt;br /&gt;other&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;Total&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="font-weight: bold;"&gt;Three months ended June 30, 2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 35%; text-align: left;"&gt;Revenue from external customers&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;13&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;43&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;56&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Cost of revenue&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;63&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: right;"&gt;63&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Gross profit/(loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(20&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Operating loss&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(472&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(27&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(69&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(562&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,130&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;Three months ended June 30, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Revenue from external customers&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;217&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;217&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Cost of revenue&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;96&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;96&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Gross profit/(loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;121&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;121&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Operating loss&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,996&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(421&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(2,417&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;Six months ended June 30, 2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Revenue from external customers&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;206&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;63&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;269&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Cost of revenue&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;36&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;63&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;99&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Gross profit/(loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;170&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;170&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Operating loss&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(956&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(14&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(69&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(768&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(1,807&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;Six months ended June 30, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Revenue from external customers&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;264&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&amp;#8212;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;264&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Cost of revenue&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;100&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Gross profit/(loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;164&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;164&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Operating (loss)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(4,262&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(750&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(5,012&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;June 30, 2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,434&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,224&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5,658&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Intangible assets&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,802&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,802&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-weight: bold;"&gt;December 31, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,123&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;581&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,704&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Intangible assets&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">217000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">217000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">264000</us-gaap:RevenuesFromExternalCustomers>

<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">264000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">56000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">13000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_3ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">43000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">269000</us-gaap:RevenuesFromExternalCustomers>

<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_UnallocatedCorporateOtherMember" unitRef="USD" decimals="-3">0</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_SoftwareAndDevicesMember" unitRef="USD" decimals="-3">206000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:RevenuesFromExternalCustomers contextRef="Context_6ME_30-Jun-2012_LegalEntityAxis_MedicsightsMember_StatementBusinessSegmentsAxis_ServiceMember" unitRef="USD" decimals="-3">63000</us-gaap:RevenuesFromExternalCustomers>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&lt;b&gt;Note 9: Convertible note and warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;On May 24, 2012, the Company entered into a securities purchase agreement (the &amp;#8220;SPA&amp;#8221;) with Hudson Bay Fund Ltd. (the &amp;#8220;Investor&amp;#8221;). The SPA provided for the purchase of an 18 month promissory note with an interest rate of 8% (the &amp;#8220;Senior Secured Convertible Note&amp;#8221; or the &amp;#8220;Note&amp;#8221;) convertible into up to 1,166,667 shares of Company Common Stock at a conversion price of $3.00 per share and a warrant (the &amp;#8220;Hudson Bay Warrant&amp;#8221; or the &amp;#8220;HB Warrant&amp;#8221;) to purchase up to 875,000 shares of Common Stock at an exercise price of $3.00 per share for proceeds of $3,500 (the &amp;#8220;Hudson Bay Transaction&amp;#8221;). The Note is convertible at the option of the holder at a conversion price of $3.00 per share and the Company can require conversion into Company Common Stock if the Weighted Average Price of the Common Stock equals or exceeds 200% of the conversion price for no less than twenty (20) Trading Days during any thirty (30) consecutive Trading Day period occurring following the issuance date, subject to a 9.99% beneficial ownership ceiling for Investor&amp;#8217;s ownership of Company Common Stock at any one time. The Note is also redeemable by the Company from and after the seven (7) month anniversary of the issuance date, subject to certain equity conditions, in cash at a price equal to the greater of (i) 125% of the Conversion Amount to be redeemed and (ii) the product of (A) the Conversion Amount being redeemed multiplied by (B) the quotient determined by dividing (x) the greatest Closing Sale Price of the shares of Common Stock during the period beginning on the date immediately preceding the date of notice of redemption and ending on the date the redemption date, by (y) the lowest Conversion Price in effect during such period, as such terms are defined in the Note. The Conversion Price of the Note is subject to adjustment in case of a combination or subdivision of stock or in the event of the grant of rights with equity features. The HB Warrant is exercisable at the option of the holder at a $3.00 per share exercise price and the Company can require exercise if the Weighted Average Price of the Company&amp;#8217;s Common Stock equals or exceeds 250% of the exercise price for no less than twenty (20) Trading Days during any thirty (30) consecutive Trading Day period occurring following the issuance date, as such terms are defined in the HB Warrant. The HB Warrant exercise price is subject to adjustment in the case of combination or subdivision of stock or in the event of the granting of any stock appreciation rights, phantom stock rights or other rights with equity features. The Note allows for payment of Common Stock in lieu of cash interest payments due pursuant to the Note. The Company obtained stockholder approval at a special meeting of the stockholders held on August 1, 2012 to issue up to 140,000 shares of Common Stock in satisfaction of interest due pursuant to the Note as well as 2,041,667 shares of Common Stock issuable pursuant to the Note and HB Warrant. In connection with the Hudson Bay Transaction, MGT agreed to issue 75,000 shares of Common Stock to Chardan Capital Markets, LLC (&amp;#8220;Chardan&amp;#8221;) and certain affiliates of Chardan in consideration of investment banking services rendered. Stockholder approval was also obtained on August 1, 2012 for the issuance of 75,000 shares of Common Stock to Chardan. The Hudson Bay Transaction required MGT and certain of its subsidiaries to provide all of its assets as collateral, to pledge the stock of its subsidiaries and certain of MGT&amp;#8217;s affiliates to execute voting and lockup agreements. The proceeds of the Hudson Bay Transaction will be used by the Company for general working capital purposes.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The proceeds of the note were allocated between the HB Warrant and the Note based on their relative fair values.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Senior Secured Convertible Note consists of the following as of:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;June&amp;#160;30,&amp;#160;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;December&amp;#160;31,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 74%; text-align: left;"&gt;Senior secured convertible note&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;3,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less: unamortized debt discount&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(957&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td
 style="text-align: left; padding-bottom: 1pt; padding-left: 0.12in;"&gt;Convertible notes&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2,543&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The conversion feature embedded in the Note was evaluated to determine if such conversion feature should be bifurcated from its host instrument and accounted for as a free standing derivative. The Company determined that the conversion feature did not need to be bifurcated.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Financing and issuance costs totaling $688 were incurred in connection with the issuance of the Note and HB Warrants. These costs include legal and placement fees, including the issuance of 75,000 shares of restricted common stock. The stock was recorded at the fair market value of $315 at the date of closing, which was accrued for at June 30, 2012, and was subsequently issued on August 9, 2012. The total costs were allocated based on relative fair values to deferred financing costs in the amount of $588 and HB Warrant issuance costs of $100. Deferred financing costs are amortized through periodic charges to non-operating expense over the maximum term of the related instrument using the effective interest method. Amortization expense for the remainder of 2012 is anticipated to be $175, with the remaining costs being fully amortized in 2013.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The following sets forth the Company&amp;#8217;s activity related to its Note during the three and six-months ended June 30, 2012 and 2011, respectively:&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="6" nowrap="nowrap"&gt;Three&amp;#160;and&amp;#160;six&amp;#160;months&amp;#160;ended,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;June 30, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center; border-bottom: black 1pt solid;" colspan="2" nowrap="nowrap"&gt;June 30, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="width: 74%; text-align: left;" nowrap="nowrap"&gt;Proceeds from issuance of convertible notes payable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;3,500&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Fair value of warrants recorded as corresponding debt discount&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;500&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Beneficial conversion feature on convertible note&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;500&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Amortization of debt discount&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;43&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="text-align: left;"&gt;Interest expense&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;23&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Amortization of deferred financing costs&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;33&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;We estimated the fair value of the HB Warrant as of the date of issuance, June 1, 2012, using a closed-formula option pricing method for barrier-type
 options that took into account the terms of the option rights of the holder and also the Company&amp;#8217;s Mandatory Exercise Option, which is consistent with using a Monte Carlo option pricing method. The options pricing methods used the following input assumptions: expected stock price volatility 75.0%; warrant term five (5) years; risk-free rate of 0.80%; dividend yield 0.0%. As the trading volume of the Company&amp;#8217;s publicly traded shares was approximately 30,000 per day and the issuable shares under the Note and HB warrant were over 2.0 million, and further because these issuable shares had not yet been registered for public sale at the issuance date, the price of the underlying shares was discounted approximately 30% for options pricing purposes. The fair value of the total HB warrants issued, given the terms of the HB Warrant agreement, was determined to be $500. The discount was recognized as an increase of additional paid-in capital and a discount to the convertible Note. The discount to the convertible Note payable is being amortized through periodic charges to other non-operating expense over the 18 month period from the date of issuance to the date the Note is due using the effective interest method.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;A beneficial conversion feature of the Note was calculated to be $500 after adjusting the effective conversion price for the fair value of the HB Warrants issued.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;The estimates discussed above require us to make assumptions based on historical results, observance of trends in our stock price, future expectations and other relevant risk factors. If other assumptions had been used, the HB Warrant valuation as calculated and recorded under the accounting guidance could have been affected.&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 15pt;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt times new roman, times, serif; margin: 0pt 0; text-align: justify; text-indent: 25pt;"&gt;Volatility is a key factor in option pricing models. For purposes of determining expected volatility, the Company used significant judgment to identify a peer group. The historical volatility of the Company&amp;#8217;s own common stock was not deemed pertinent to the estimate, because of the recent change in the Company&amp;#8217;s operations and business plan. The risk-free rate for the period coincides with the expected life of the HB Warrants and is based on the U.S. Treasury Department yield curve in effect at time of closing.&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:InterestAndOtherIncomeTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 25.0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company&amp;#8217;s interest and other (expense)/income were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 85%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Three&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Six&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="width: 48.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="48%" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Interest (expense)/income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(23&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;11&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in
 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(23&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;32&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Other (expense)/income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(2&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4; mso-yfti-lastrow: yes;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(23&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;11&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding:
 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(25&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;32&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:InterestAndOtherIncomeTableTextBlock>
<mgt:SeniorSecuredConvertibleNoteTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 25.0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Senior Secured Convertible Note consists of the following as of:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 85%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;June&amp;#160;30,&amp;#160;2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;December&amp;#160;31,&amp;#160;2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="width: 74.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="74%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Senior secured convertible note&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Less: unamortized debt discount&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(957&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3; mso-yfti-lastrow: yes;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 8.65pt;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Convertible notes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,543&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt
 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 8.65pt;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 1.0pt 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</mgt:SeniorSecuredConvertibleNoteTableTextBlock>
<mgt:ActivityOfConvertibleNoteTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 15.0pt;"&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt; text-align: justify; text-indent: 25.0pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;The following sets forth the Company&amp;#8217;s activity related to its Note during the three and six-months ended June 30, 2012 and 2011, respectively:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in; margin-bottom: .0001pt;"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 85%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="6" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;Three&amp;#160;and&amp;#160;six&amp;#160;months&amp;#160;ended,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="padding: 0in 0in 0in 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 1.0pt 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;June 30, 2012&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border: none; border-bottom: solid black 1.0pt; padding: 0in 0in 0in 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;June 30, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in 0in 1.0pt 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="width: 74.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="74%" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Proceeds from issuance of convertible notes payable&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;3,500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1.0%; background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Fair value of warrants recorded as corresponding debt discount&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4;"&gt;
&lt;td style="background: #ccffcc; padding: 0in" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Beneficial conversion feature on convertible note&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;500&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 5;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Amortization of debt discount&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;43&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 6;"&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Interest expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;23&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 7; mso-yfti-lastrow: yes;"&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;Amortization of deferred financing costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;33&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in 0in 0in 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</mgt:ActivityOfConvertibleNoteTableTextBlock>
<mgt:StockIssuedWarrantsFairValue contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">400000</mgt:StockIssuedWarrantsFairValue>
<mgt:PercentageForConsiderationOfPatent contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">0.55</mgt:PercentageForConsiderationOfPatent>
<mgt:PercentageForConsiderationOfPatentByNonControllingInterests contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">0.45</mgt:PercentageForConsiderationOfPatentByNonControllingInterests>
<mgt:ConsiderationOfPatentByNonControllingInterestsValue contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">819000</mgt:ConsiderationOfPatentByNonControllingInterestsValue>
<us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">800000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="4">0.0080</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_30-Jun-2012_IssuanceOfWarrantsAxis_BlackScholesPricingMember" unitRef="pure" decimals="4">0.0080</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_30-Jun-2012">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">0.75</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30-Jun-2012" unitRef="USD_per_Share" decimals="0">4</us-gaap:FairValueAssumptionsExercisePrice>
<mgt:PatentTransferDescription contextRef="Context_6ME_30-Jun-2012">Pursuant to the Sale Agreement, (i) J&amp;amp;S sold certain patents to MGT Gaming in exchange for 1,000 shares (constituting 100% ownership) of MGT Gaming Common Stock, par value $0.001; (ii) the Company purchased from J&amp;amp;S 550 MGT Gaming Shares constituting 55% ownership in exchange for $200 cash and a four (4) year warrant to purchase 350,000 shares of the Company's common stock at an exercise price of $4.00 per share, subject to certain anti-dilution provisions (the "Warrants"); (iii) the Company and J&amp;amp;S agreed to grant rights of first refusal, "tag-along" and "drag-along" rights to one another with respect to their respective MGT Gaming Shares.</mgt:PatentTransferDescription>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">102000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">204000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">204000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">204000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">204000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
<mgt:IssuanceOfWarrantsInAnticipation contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">50000</mgt:IssuanceOfWarrantsInAnticipation>
<mgt:PaymentToAcquireIntellactualProperty contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">200000</mgt:PaymentToAcquireIntellactualProperty>
<mgt:PatentsFairValueDisclosure contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">1819000</mgt:PatentsFairValueDisclosure>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_6ME_30-Jun-2012">&lt;p style="text-align: justify; line-height: normal; text-indent: 25pt; margin: 0in 0in 0pt;" class="msonormal"&gt;The fair value was determined as follows:&lt;/p&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 80%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="width: 87%; background: #ccffcc; border: #ece9d8; padding: 0in;" valign="bottom" width="87%"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;Cash&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; border: #ece9d8; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; border: #ece9d8; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 10%; background: #ccffcc; border: #ece9d8; padding: 0in;" valign="bottom" width="10%"&gt;
&lt;p align="right" style="text-align: right; line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;200&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; border: #ece9d8; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="background: white; border: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;Fair value of warrants issued&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; border: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; border: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; border: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right; line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;800&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; border: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;Fair value of intangible asset contributed by non-controlling interest&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: #ece9d8; background: #ccffcc; border-top: #ece9d8; border-right: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: #ece9d8; background: #ccffcc; border-top: #ece9d8; border-right: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right; line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;819&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3; mso-yfti-lastrow: yes;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;Total&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: #ece9d8; background: white; border-top: #ece9d8; border-right: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;$&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: #ece9d8; background: white; border-top: #ece9d8; border-right: #ece9d8; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right; line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;1,819&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in; border: #ece9d8;" valign="bottom"&gt;
&lt;p style="line-height: normal; margin: 0in 0in 0pt;" class="msonormal"&gt;&amp;#160;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">315000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">957000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">17000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<mgt:InterestAndOtherNonOperatingIncomeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">11000</mgt:InterestAndOtherNonOperatingIncomeExpense>
<mgt:InterestAndOtherNonOperatingIncomeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">32000</mgt:InterestAndOtherNonOperatingIncomeExpense>
<mgt:InterestAndOtherNonOperatingIncomeExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">-23000</mgt:InterestAndOtherNonOperatingIncomeExpense>
<mgt:InterestAndOtherNonOperatingIncomeExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-25000</mgt:InterestAndOtherNonOperatingIncomeExpense>
<mgt:OtherIncomeExpenseNonOperating contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:OtherIncomeExpenseNonOperating>
<mgt:OtherIncomeExpenseNonOperating contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</mgt:OtherIncomeExpenseNonOperating>
<mgt:OtherIncomeExpenseNonOperating contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:OtherIncomeExpenseNonOperating>
<mgt:OtherIncomeExpenseNonOperating contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">-2000</mgt:OtherIncomeExpenseNonOperating>
<mgt:IncreaseInAssignmentOfStock contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">21000</mgt:IncreaseInAssignmentOfStock>
<mgt:IncreaseInAssignmentOfStock contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</mgt:IncreaseInAssignmentOfStock>
<mgt:SeniorSecuredConvertibleDebtNonCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</mgt:SeniorSecuredConvertibleDebtNonCurrent>
<mgt:SeniorSecuredConvertibleDebtNonCurrent contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">3500000</mgt:SeniorSecuredConvertibleDebtNonCurrent>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">3500000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">3500000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">43000</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:InterestExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME_30-Jun-2012" unitRef="USD" decimals="-3">23000</us-gaap:InterestExpense>
<mgt:PercentageOfConversionAmountToBeRedeemed contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">1.25</mgt:PercentageOfConversionAmountToBeRedeemed>
<mgt:DebtInstrumentConvertibleTermsOfConversionFeatureWarrants contextRef="Context_6ME_30-Jun-2012">The HB Warrant is exercisable at the option of the holder at a $3.00 per share exercise price and the Company can require exercise if the Weighted Average Price of the Company's Common Stock equals or exceeds 250% of the exercise price for no less than twenty (20) Trading Days during any thirty (30) consecutive Trading Day period occurring following the issuance date, as such terms are defined in the HB Warrant.</mgt:DebtInstrumentConvertibleTermsOfConversionFeatureWarrants>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">875000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="Context_6ME_30-Jun-2012">The Note is convertible at the option of the holder at a conversion price of $3.00 per share and the Company can require conversion into Company Common Stock if the Weighted Average Price of the Common Stock equals or exceeds 200% of the conversion price for no less than twenty (20) Trading Days during any thirty (30) consecutive Trading Day period occurring following the issuance date, subject to a 9.99% beneficial ownership ceiling for Investor's ownership of Company Common Stock at any one time.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
<mgt:MaximumCommonStockIssuableInSatisfactionOfInterestDue contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">140000</mgt:MaximumCommonStockIssuableInSatisfactionOfInterestDue>
<mgt:MaximumCommonStockIssuablePursuantToNoteAndWarrant contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">2041667</mgt:MaximumCommonStockIssuablePursuantToNoteAndWarrant>
<mgt:IssuableOfCommonStockForInvestmentBankingServices contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">75000</mgt:IssuableOfCommonStockForInvestmentBankingServices>
<mgt:FinancingAndIssuanceCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">688000</mgt:FinancingAndIssuanceCosts>
<mgt:IssuanceOfRestrictedCommonStock contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">75000</mgt:IssuanceOfRestrictedCommonStock>
<mgt:RestrictedCommonStockFairMarketValue contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">315000</mgt:RestrictedCommonStockFairMarketValue>

<mgt:WarrantIssuanceCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">100000</mgt:WarrantIssuanceCosts>
<mgt:MaximumTradingSharesPerDay contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">30000</mgt:MaximumTradingSharesPerDay>
<mgt:MaximumIssuableSharesUnderNoteAndWarrants contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="-5">2000000</mgt:MaximumIssuableSharesUnderNoteAndWarrants>
<mgt:MaximumPercentageOfStockOptionsDiscounted contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">0.30</mgt:MaximumPercentageOfStockOptionsDiscounted>
<mgt:WarrantsIssuedFairValue contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">500000</mgt:WarrantsIssuedFairValue>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">175000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="3">0.000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:DebtInstrumentConvertibleEffectiveInterestRate contextRef="Context_6ME_30-Jun-2012" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentConvertibleEffectiveInterestRate>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_6ME_30-Jun-2012" unitRef="shares" decimals="0">1166667</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_30-Jun-2012" unitRef="USD_per_Share" decimals="2">3.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:ProfitLoss>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalReverseStockSplit>
<us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
<mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</mgt:FairValueOfIntangibleAssetContributedByNonControllingInterest>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithAcquisitionOfIntangibleAssets>
<mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</mgt:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithIssuanceOfConvertibleNote>

<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:ProfitLoss contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:ProfitLoss>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax contextRef="Context_6ME_30-Jun-2012_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_MoneygateGroupMember" unitRef="USD" decimals="-3">81000</us-gaap:GainLossOnSaleOfEquityInvestments>
<us-gaap:InterestAndFeeIncomeLoansAndLeases contextRef="Context_3ME_31-Mar-2011_RelatedPartyTransactionsByRelatedPartyAxis_DunamisCapitalMember" unitRef="USD" decimals="-3">48000</us-gaap:InterestAndFeeIncomeLoansAndLeases>
<mgt:AdditionalPatentTransferDescription contextRef="Context_6ME_30-Jun-2012">Additionally, the Company has the right to purchase an additional 250 MGT Gaming Shares from J&amp;S in exchange for a cash payment of $1,000 and a four (4) year warrant to purchase 250,000 shares of the Company's common stock for an exercise price of the lower of (i) $6.00 per share and (ii) 110% of the closing price of the common stock on the date of issuance.</mgt:AdditionalPatentTransferDescription>
<xbrli:context id="Context_6ME_30-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:LaddcapValuePartnersIiiLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:InterestExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestExpense>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:InterestExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">0</us-gaap:InterestExpense>
<xbrli:context id="Context_As_Of_31-Jan-2012_LegalEntityAxis_MedicsightsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-01-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Jan-2012_LegalEntityAxis_MedicsightsMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Jan-2012_LegalEntityAxis_MedicsightsMember" unitRef="shares" decimals="0">1</us-gaap:CommonStockSharesIssued>
<xbrli:context id="Context_As_Of_01-Jun-2012_LegalEntityAxis_MgtGamingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-06-01</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_01-Jun-2012_LegalEntityAxis_MgtGamingMember" unitRef="shares" decimals="0">550</us-gaap:CommonStockSharesIssued>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_RelatedPartyTransactionsByRelatedPartyAxis_D4DLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MedicsightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:D4DLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<mgt:PaymentsOfServiceAgreement contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MedicsightsMember_RelatedPartyTransactionsByRelatedPartyAxis_D4DLimitedMember" unitRef="USD" decimals="-3">315000</mgt:PaymentsOfServiceAgreement>
<xbrli:context id="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember_RelatedPartyTransactionsByRelatedPartyAxis_D4DLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mgt:MgtGamingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:D4DLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<mgt:PaymentsOfServiceAgreement contextRef="Context_6ME_30-Jun-2011_LegalEntityAxis_MgtGamingMember_RelatedPartyTransactionsByRelatedPartyAxis_D4DLimitedMember" unitRef="USD" decimals="-3">304000</mgt:PaymentsOfServiceAgreement>
<mgt:OperatingLeasesMonthltyRentalPayments contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">13000</mgt:OperatingLeasesMonthltyRentalPayments>
<mgt:OperatingLeasesMonthltyRentalPayments contextRef="Context_6ME_30-Jun-2011" unitRef="GBP" decimals="-3">8000</mgt:OperatingLeasesMonthltyRentalPayments>
<mgt:OperatingLeasesRentalDeposit contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">25000</mgt:OperatingLeasesRentalDeposit>
<mgt:OperatingLeasesRentalDeposit contextRef="Context_6ME_30-Jun-2011" unitRef="GBP" decimals="-3">16000</mgt:OperatingLeasesRentalDeposit>
<us-gaap:LaborAndRelatedExpense contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">10000</us-gaap:LaborAndRelatedExpense>
<mgt:OperatingLeasesRefundableRentalDeposit contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">39000</mgt:OperatingLeasesRefundableRentalDeposit>
<mgt:PaymentsForFinancialAdvisoryAndConsultingAgreement contextRef="Context_6ME_30-Jun-2012" unitRef="USD" decimals="-3">5000</mgt:PaymentsForFinancialAdvisoryAndConsultingAgreement>
<mgt:OperatingLeasesRentalPayments contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="-3">240000</mgt:OperatingLeasesRentalPayments>
<xbrli:context id="Context_3ME_30-Jun-2011_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:LaddcapValuePartnersIiiLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-04-01</xbrli:startDate><xbrli:endDate>2011-06-30</xbrli:endDate></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_30-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001601</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgt:LaddcapValuePartnersIiiLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-06-30</xbrli:instant></xbrli:period></xbrli:context>
	<mgt:LineOfCreditFacilityAccruedCommitmentFee contextRef="Context_As_Of_30-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_LaddcapValuePartnersIiiLlcMember" unitRef="USD" decimals="-3">10000</mgt:LineOfCreditFacilityAccruedCommitmentFee>

<mgt:DeferredFinancingCosts contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="-3">588000</mgt:DeferredFinancingCosts>
</xbrli:xbrl>
